High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast

Modern Pathology

Volumn 23, Issue 1, 2010, Pages 27-37

  Troxell, Megan L ^a   Levine, Judith ^a   Beadling, Carol ^a   Warrick, Andrea ^a   Dunlap, Jennifer ^a   Presnell, Ajia ^a   Patterson, Janice ^a   Shukla, Arielle ^a,c   Olson, Neal R ^b   Heinrich, Michael C ^a,b,c   Corless, Christopher L ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Kaiser Permanente Northwest ^*  (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

AKT1; Breast; Papillary carcinoma; Papilloma; Phosphoinositol 3 kinase (PIK3CA)

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INOSITOL PHOSPHATE; K RAS PROTEIN; PHOSPHOINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST HYPERPLASIA; BREAST PAPILLOMA; CARCINOMA IN SITU; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE SEQUENCE; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MUTATION RATE; ONCOGENE H RAS; ONCOGENE N RAS; PAPILLARY CARCINOMA; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 73949156234     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.142     Document Type: Article

References (51)

1. Mulligan AM, O'Malley FP. Papillary lesions of the breast: a review. Adv Anat Pathol 2007;14:108-119.
2. Noguchi S, Motomura K, Inaji H, et al. Clonal analysis of solitary intraductal papilloma of the breast by means of polymerase chain reaction. Am J Pathol 1994;144: 1320-1325. (Pubitemid 24172094)
3. Noguchi S, Aihara T, Koyama H, et al. Clonal analysis of benign and malignant human breast tumors by means of polymerase chain reaction. Cancer Lett 1995;90:57-63.
4. Tsuda H, Takarabe T, Inazawa J, et al. Detection of numerical alterations of chromosomes 3, 7, 17 and X in low-grade intracystic papillary tumors of the breast by multi-color fluorescence in situ hybridization. Breast Cancer 1997;4:247-252.
5. Lininger RA, Park WS, Man YG, et al. LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. Hum Pathol 1998;29:1113-1118.
6. Di Cristofano C, Mrad K, Zavaglia K, et al. Papillary lesions of the breast: a molecular progression? Breast Cancer Res Treat 2005;90:71-76.
7. Boecker W, Buerger H, Schmitz K, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 2001;195:415-421.
8. Dietrich CU, Pandis N, Teixeira MR, et al. Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. Int J Cancer 1995;60:49-53.
9. Komoike Y, Motomura K, Inaji H, et al. Diagnosis of ductal carcinoma in situ (DCIS) and intraductal papilloma using fluorescence in situ hybridization (FISH) analysis. Breast Cancer 2000;7:332-336.
10. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3: 1221-1224.
11. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol-3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-1345.
12. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-775. (Pubitemid 41351083)
13. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepato-cellular carcinomas. Oncogene 2005;24:1477-1480.
14. Li SY, Rong M, Grieu F, et al. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006;96:91-95.
15. Liang X, Lau QC, Salto-Tellez M, et al. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese. Cancer Biol Ther 2006;5: 544-548.
16. Maruyama N, Miyoshi Y, Taguchi T, et al. Clinico-pathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007;13:408-414.
17. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559.
18. Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007;13:3577-3584.
19. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-6091.
20. Dunlap J, Le C, Shukla A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 2009; doi:10.1007/ s10549-009-0406-411
21. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444.
22. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. Oncogene 2008; doi:10.1038/ onc.2008.170.
23. Kim MS, Jeong EG, Yoo NJ, et al. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008;98: 1533-1535.
24. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
25. Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 2005;17:141-149.
26. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-5496.
27. Page DL, Rogers LW. Combined histologic and cytolo-gic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23:1095-1097.
28. Collins LC, Schnitt SJ. Papillary lesions of the breast: selected diagnostic and management issues. Histo-pathology 2008;52:20-29.
29. Rosen PP. Papillary Carcinoma. In: Rosen PP (ed). Rosen's Breast Pathology, Vol.1, 3rd edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2009, pp 429-448.
30. Maluf HM, Koerner FC. Solid papillary carcinoma of the breast. A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Am J Surg Pathol 1995;19:1237-1244.
31. Rosen PP. Ductal hyperplasia: usual and atypical. In: Rosen PP (ed). Rosen's Breast Pathology, Vol.1, 3rd edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2009, pp 235-238.
32. Pratilas CA, Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008;68:9375-9383.
33. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;100:5974-5979.
34. Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 2003;5:313-319.
35. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350: 1430-1441.
36. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol 2005;205:248-254.
37. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005;143:446-457.
38. Moulis S, Sgroi DC. Re-evaluating early breast neopla-sia. Breast Cancer Res 2008;10:302.
39. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
40. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005;65: 10992-11000.
41. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562-4567.
42. O'Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703.
43. Werner M, Mattis A, Aubele M, et al. 20q13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast. Virchows Arch 1999;435:469-472.
44. Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol 2000;9:14-19.
45. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001;8:47-61.
46. Gong G, DeVries S, Chew KL, et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001;7:2410-2414.
47. Jones C, Merrett S, Thomas VA, et al. Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast. J Pathol 2003;199:152-156.
48. Yu Q, Niu Y, Yu Y, et al. Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay. Breast Cancer Res Treat 2009;114: 433-440.
49. Malaney S, Daly RJ. The ras signaling pathway in mammary tumorigenesis and metastasis. J Mammary Gland Biol Neoplasia 2001;6:101-113.
50. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-531.
51. Esposito N, Nikiforova M, Nikiforov Y, et al. Muta-tional Profile of RAS and BRAF genes in papillary lesions of the breast: identification of a common HRAS mutation in intracystic papillary carcinoma. Mod Pathol 2008;21:47A.